在辅助剂诱导的类风湿关节炎上改善梅利丁:集成的转录组和代谢组
Linfu Yang1, Xiying He2, Yunfei Xue1
1Yunnan Provincial Engineering and Research Center for Sustainable Utilization of Honey Bee Resources, Eastern Bee Research Institute, College of Animal Science and Technology, Yunnan Agricultural University, Kunming 650201, China.
International journal of biological macromolecules
|May 12, 2024
概括
梅利丁 (MLT) 通过减少关节炎症和损伤,有效地减轻老鼠的类风湿性关节炎 (RA) 症状. 这项研究详细介绍了MLT.
科学领域:
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
- 基因组学就是基因组学.
背景情况:
- 类风湿性关节炎 (RA) 是一种慢性自身免疫性疾病,治疗疗法有限.
- 常规的RA疗法,如德克萨米他和甲醇,有潜在的不良影响.
- 梅利丁 (MLT) 作为一种天然的抗风湿剂显示出希望,但其在RA中的分子机制需要进一步研究.
研究的目的:
- 在风湿性关节炎 (RA) 的小鼠模型中研究梅利丁 (MLT) 的治疗疗效.
- 通过转录组和代谢组分析,阐明MLT抗RA作用背后的分子机制.
- 验证关键RA相关基因的调制,并评估MLT与炎症媒介的结合相互作用.
主要方法:
- 风湿性关节炎在使用完整弗洛恩德辅助剂 (CFA) 的老鼠中被诱导并用MLT治疗.
- 进行了转录组和代谢组分析,以确定MLT调节的途径和生物标志物.
- 定量实时PCR (qRT-PCR) 和分子对接模拟 (AutoDock Vina) 用于验证和相互作用研究.
主要成果:
- MLT治疗显著减少了关节发红,胀,炎症细胞透和关节损伤.
- 转录组和代谢组数据表明MLT对细胞因子/免疫反应途径和生物标志物如斯芬戈米林,脂肪酸和黄类药物的调节.
- qRT-PCR证实了MLT对关键炎症基因 (Il6,Jak2,Stat3,Ptx3) 的下调,分子对接显示MLT与TNF-α和IL-1β结合稳定.
结论:
- 梅利丁 (MLT) 在缓解类风湿性关节炎 (RA) 中表现出显著的治疗疗效.
- 这项研究为MLT对RA基因表达和代谢概况的影响提供了全面的见解.
- MLT代表了一种潜在的天然治疗剂,用于治疗类风湿性关节炎.
相关概念视频
Combined Effects of Drugs: Synergism
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents
Diarrhea is characterized by the occurrence of frequent, watery bowel movements. Various factors can trigger diarrhea, including viral or bacterial infections, foodborne illnesses, side effects from certain medications, and underlying digestive disorders. If not adequately managed, diarrhea can lead to complications such as dehydration, electrolyte imbalances, and nutrient deficiencies. Severe diarrhea can lead to significant weight loss, malnutrition, and weakened immune function.
Adsorbents...
Adsorbents...
Drugs for Treatment of Diarrhea-Predominant IBS
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...


